Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium: A Step Towards Advancing Its Pipeline

Chimerix (NASDAQ: CMRX), a biopharmaceutical company dedicated to developing life-saving medicines, has announced its participation in the upcoming JonesTrading Virtual Precision Medicine Symposium. The event, scheduled for Monday, February 3, 2025, at 11:00 a.m. ET, will feature a fireside chat with Mike Andriole, Chief Executive Officer, and Tom Riga, Chief Operating and Commercial Officer. An audio webcast of the panel discussion will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

Chimerix's mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company's most advanced clinical-stage development program, dordaviprone, is in development for H3 K27M-mutant glioma. The company is also conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data. By participating in the JonesTrading Virtual Precision Medicine Symposium, Chimerix aims to showcase its pipeline, share recent clinical data, and engage with investors, potential partners, and industry experts.

The presentation at the symposium aligns with Chimerix's broader pipeline development and commercialization strategies. It provides an opportunity for the company to:

1. Demonstrate the potential of dordaviprone: The presentation will highlight positive data from the 50-patient efficacy analysis of ONC201 (now known as dordaviprone) for the treatment of recurrent H3 K27M-mutant diffuse midline glioma. This data showcases the drug's durable and clinically meaningful efficacy, setting the stage for future study of ONC201 earlier in treatment and potentially expanding its use in other indications.
2. Expand the pipeline: Chimerix is conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data. The presentation at the symposium can help generate interest and support for this additional pipeline asset, further diversifying the company's portfolio of potential life-saving medicines.
3. Strengthen partnerships and collaborations: Engaging in symposia and conferences like this one allows Chimerix to network with other industry professionals, potential partners, and investors. These connections can facilitate collaborations and strategic alliances that support the company's mission and accelerate the development and commercialization of its pipeline.
4. Enhance the company's reputation: By sharing positive data and progress on its pipeline, Chimerix can enhance its reputation as a leader in developing innovative medicines for deadly diseases. This can attract more investment, talent, and support for the company's mission.

In conclusion, Chimerix's participation in the JonesTrading Virtual Precision Medicine Symposium is an integral part of the company's broader pipeline development and commercialization strategies. The presentation provides an opportunity for Chimerix to showcase its progress, expand its pipeline, strengthen partnerships, enhance its reputation, and prepare for regulatory submissions. Investors and industry professionals should pay close attention to the company's presentation, as it may provide valuable insights into the company's future prospects and potential investment opportunities.